Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Rao, Jia ^a   Xu, Duo Rong ^a   Zheng, Fei Meng ^b   Long, Zi Jie ^a   Huang, Sheng Shan ^a   Wu, Xing ^a   Zhou, Wei Hua ^a   Huang, Ren Wei ^a   Liu, Quentin ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; CD34 ANTIGEN; CURCUMIN; DAUNORUBICIN; HOE 33342; LIPOCORTIN 5; MATRIX METALLOPROTEINASE; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROPIDIUM IODIDE; PROTEIN BCL 2; SMALL INTERFERING RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CD34 SELECTION; CELL ASSAY; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL ISOLATION; CELL PROLIFERATION; CELL STRAIN KG1A; CELL STRAIN U937; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG STRUCTURE; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GIEMSA STAIN; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; KASUMI 1 CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MONONUCLEAR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; AGED; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROTEIN PROCESSING; TUMOR CELL LINE;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; DAUNORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; G1 PHASE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MIDDLE AGED; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; RNA, SMALL INTERFERING; S PHASE;

EID: 79956046171     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-71     Document Type: Article

References (48)

1. Geller RB, Zahurak M, Hurwitz CA, Burke PJ, Karp JE, Piantadosi S, Civin CI. Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem-cell glycoprotein CD34 (My10). Br J Haematol 1990, 76:340-347. 10.1111/j.1365-2141.1990.tb06365.x, 1702006.
2. Myint H, Lucie NP. The prognostic significance of the CD34 antigen in acute myeloid leukaemia. Leuk Lymphoma 1992, 7:425-429. 10.3109/10428199209049798, 1283545.
3. Repp R, Schaekel U, Helm G, Thiede C, Soucek S, Pascheberg U, Wandt H, Aulitzky W, Bodenstein H, Sonnen R, Link H, Ehninger G, Gramatzki M, . AML-SHG Study Group Immunophenotyping is an independent factor for risk stratification in AML. Cytometry B Clin Cytom 2003, 53:11-19. AML-SHG Study Group.
4. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005, 106:1154-1163. 10.1182/blood-2005-01-0178, 15870183.
5. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006, 368:1894-1907. 10.1016/S0140-6736(06)69780-8, 17126723.
6. Shman TV, Fedasenka UU, Savitski VP, Aleinikova OV. CD34+ leukemic subpopulation predominantly displays lower spontaneous apoptosis and has higher expression levels of Bcl-2 and MDR1 genes than CD34- cells in childhood AML. Ann Hematol 2008, 87:353-360. 10.1007/s00277-008-0439-2, 18228020.
7. Baer MR, Stewart CC, Dodge RK, Leget G, Sule N, Mrozek K, Schiffer CA, Powell BL, Kolitz JE, Moore JO, Stone RM, Davey FR, Carroll AJ, Larson RA, Bloomfield CD. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 2001, 97:3574-3580. 10.1182/blood.V97.11.3574, 11369653.
8. Bailly JD, Muller C, Jaffrezou JP, Demur C, Gassar G, Bordier C, Laurent G. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia 1995, 9:799-807.
9. Bailly JD, Skladanowski A, Bettaieb A, Mansat V, Larsen AK, Laurent G. Natural resistance of acute myeloid leukemia cell lines to mitoxantrone is associated with lack of apoptosis. Leukemia 1997, 11:1523-1532. 10.1038/sj.leu.2400762, 9305608.
10. van-Stijn A, van-der-Pol MA, Kok A, Bontje PM, Roemen GM, Beelen RH, Ossenkoppele GJ, Schuurhuis GJ. Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukemia. Haematologica 2003, 88:497-508.
11. Suarez L, Vidriales MB, Moreno MJ, Lopez A, Garcia-Larana J, Perez-Lopez C, Tormo M, Lavilla E, Lopez-Berges MC, de Santiago M, San Miguel JF, Orfao A, . PETHEMA Cooperative Group Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells. Haematologica 2005, 90:54-59. PETHEMA Cooperative Group.
12. Chang H, Salma F, Yi QL, Patterson B, Brien B, Minden MD. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res 2004, 28:43-48. 10.1016/S0145-2126(03)00180-2, 14630079.
13. Kim YH, Park JW, Lee JY, Surh YJ, Kwon TK. Bcl-2 overexpression prevents daunorubicin-induced apoptosis through inhibition of XIAP and Akt degradation. Bioche Pharmacol 2003, 66:1779-1786.
14. Konopleva M, Zhao S, Hu W, Jiang S, Snell V, Weidner D, Jackson CE, Zhang X, Champlin R, Estey E, Reed JC, Andreeff M. The anti-apoptotic genes Bcl-xl and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Brit J Haematol 2002, 18:521-534.
15. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 2008, 267:133-164. 10.1016/j.canlet.2008.03.025, 18462866.
16. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 2009, 30:85-94. 10.1016/j.tips.2008.11.002, 19110321.
17. Bae JH, Park JW, Kwon TK. Ruthenium red, inhibitor of mitochondrial Ca2+ uniporter, inhibits curcumin-induced apoptosis via the prevention of intracellular Ca2+ depletion and cytochrome c release. Biochem Biophys Res Commun 2003, 303:1073-1079. 10.1016/S0006-291X(03)00479-0, 12684045.
18. Mukherjee S, Ghosh U, Bhattacharyya NP, Bhattacharya RK, Dey S, Roy M. Curcumin-induced apoptosis in human leukemia cell HL-60 is associated with inhibition of telomerase activity. Mol Cell Biochem 2007, 297:31-39. 10.1007/s11010-006-9319-z, 17096185.
19. Hussain AR, Al-Rasheed M, Manogaran PS, Al-Hussein KA, Platanias LC, Al-Kuraya K, Uddin S. Curcumin induces apoptosis via inhibition of PI3'-kinase/AKT pathway in acute T cell leukemias. Apoptosis 2006, 11:245-254. 10.1007/s10495-006-3392-3, 16502262.
20. Tomita M, Kawakami H, Uchihara JN, Okudaira T, Masuda M, Takasu N, Matsuda T, Ohta T, Tanaka Y, Ohshiro K, Mori N. Curcumin (diferuloylmethane) inhibits constitutive active NF-kappaB, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells. Int J Cancer 2006, 118:765-772. 10.1002/ijc.21389, 16106398.
21. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008, 269:199-225. 10.1016/j.canlet.2008.03.009, 18479807.
22. Lev-Ari S, Starr A, Vexler A, Karaush V, Loew V, Greif J, Fenig E, Aderka D, Ben-Yosef R. Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity. Anticancer Res 2006, 26:4423-4430.
23. Shishodia S, Amin HM, Lai R, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 2005, 70:700-713. 10.1016/j.bcp.2005.04.043, 16023083.
24. Yu S, Shen G, Khor TO, Kim JH, Kong AN. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol Cancer Ther 2008, 7:2609-2620. 10.1158/1535-7163.MCT-07-2400, 2596943, 18790744.
25. Choi BH, Kim CG, Lim Y, Shin SY, Lee YH. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett 2008, 259:111-118. 10.1016/j.canlet.2007.10.003, 18006147.
26. Prasad CP, Rath G, Mathur S, Bhatnagar D, Ralhan R. Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/beta-catenin signaling. Chem Biol Interact 2009, 181:263-271. 10.1016/j.cbi.2009.06.012, 19573523.
27. Wang Z, Zhang Y, Banerjee S, Li Y, Sarkar FH. Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 2006, 106:2503-2513. 10.1002/cncr.21904, 16628653.
28. Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006, 6:10-13. 10.1186/1472-6882-6-10, 1434783, 16545122.
29. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008, 14:4491-4499. 10.1158/1078-0432.CCR-08-0024, 18628464.
30. Koeffler HP, Billing R, Lusis AJ, Sparkes R, Golde DW. An undifferentiated variant derived from the human acute myelogenous leukemia cell line (KG-1). Blood 1980, 56:265-273.
31. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991, 77:2031-2036.
32. Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D'Alessandro N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett 2005, 16:53-65.
33. Anderson EM, Miller P, Ilsley D, Marshall W, Khvorova A, Stein CA, Benimetskaya L. Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature. Cancer Gene Ther 2006, 13:406-414. 10.1038/sj.cgt.7700901, 16195754.
34. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58:621-681. 10.1124/pr.58.3.10, 16968952.
35. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010, 70:440-446. 10.1158/0008-5472.CAN-09-1947, 20068163.
36. Jin ZJ. [Addition in drug combination (author's transl)]. Zhongguo Yao Li Xue Bao 1980, 1:70-76.
37. Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res 1983, 43:3417-3421.
38. Lagadinou ED, Ziros PG, Tsopra OA, Dimas K, Kokkinou D, Thanopoulou E, Karakantza M, Pantazis P, Spyridonidis A, Zoumbos NC. c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia. Leukemia 2008, 22:1899-1908. 10.1038/leu.2008.192, 18650843.
39. Henry-Mowatt J, Dive C, Martinou JC, James D. Role of mitochondrial membrane permeabilization in apoptosis and cancer. Oncogene 2004, 23:2850-2860. 10.1038/sj.onc.1207534, 15077148.
40. Park J, Ayyappan V, Bae EK, Lee C, Kim BS, Kim BK, Lee YY, Ahn KS, Yoon SS. Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. Mol Oncol 2008, 2:317-326. 10.1016/j.molonc.2008.09.006, 19383353.
41. Duarte VM, Han E, Veena MS, Salvado A, Suh JD, Liang LJ, Faull KF, Srivatsan ES, Wang MB. Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKKβ protein of the NFκB pathway. Mol Cancer Ther 2010, 9:2665-2675. 10.1158/1535-7163.MCT-10-0064, 20937593.
42. Yu Y, Kanwar SS, Patel BB, Nautiyal J, Sarkar FH, Majumdar AP. Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX. Transl Oncol 2009, 2:321-328. 2781082, 19956394.
43. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284. 10.1038/nrc1590, 15803154.
44. Pesakhov S, Khanin M, Studzinski GP, Danilenko M. Distinct combinatorial effects of the plant polyphenols curcumin, carnosic acid, and silibinin on proliferation and apoptosis in acute myeloid leukemia cells. Nutr Cancer 2010, 62:811-824. 10.1080/01635581003693082, 2911976, 20661831.
45. Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 2005, 14:120-125.
46. Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, Sung B, Tharakan ST, Misra K, Priyadarsini IK, Rajasekharan KN, Aggarwal BB. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 2008, 76:1590-1611. 10.1016/j.bcp.2008.08.008, 18775680.
47. Kurien BT, Scofield RH. Oral administration of heat-solubilized curcumin for potentially increasing curcumin bioavailability in experimental animals. Int J Cancer 2009, 125:1992-1993. 10.1002/ijc.24547, 2747637, 19618459.
48. Kurien BT, Singh A, Matsumoto H, Scofield RH. Improving the solubility and pharmacological efficacy of curcumin by heat treatment. Assay Drug Dev Technol 2007, 5:567-576. 10.1089/adt.2007.064, 17767425.